Algen Biotechnologies vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI drug discovery platform mapping functional gene networks for novel target identification; $12.63M from Viking Global and YC W20 applying computational genomics to decode disease biology.
About
Algen Biotechnologies is a San Francisco-based drug discovery company that builds computational platforms to decode functional gene networks — using machine learning and genomic data to map the relationships between genes, understand how gene interactions drive disease, and identify novel therapeutic targets that traditional drug discovery approaches miss because they analyze genes in isolation. Founded in 2018 by Chun Hao Huang and Christine Du and a Y Combinator W20 graduate, Algen raised $12.63 million total including a $9 million Seed VC-II round led by Viking Global Investors in February 2022.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.